Novartis Ag (NVS) Capital Expenditures (2009 - 2026)

Novartis Ag has reported Capital Expenditures for 18 years, with the latest figure at $321.0 million in Q2 2026.

• Quarterly Capital Expenditures fell 3.02% year-over-year to $321.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$988.0 million (down 23.19% YoY) and the FY2025 annual result came in at $1.5 billion, up 13.32% from the prior year.
• Capital Expenditures climbed to $321.0 million in Q2 2026 per NVS's latest filing, from -$346.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $331.0 million in Q2 2025 and troughed at -$609.0 million in Q4 2025.
• A 5-year average of -$243.2 million and a median of -$258.5 million in 2022 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures plunged 37.44% in 2024, then jumped 227.31% in 2025.
• Over 5 years, Capital Expenditures stood at -$306.0 million in 2022, then plunged by 32.68% to -$406.0 million in 2023, then slumped by 37.44% to -$558.0 million in 2024, then declined by 9.14% to -$609.0 million in 2025, then soared by 152.71% to $321.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $321.0 million, -$346.0 million, and -$609.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.